SCM
CRL icon

Sandler Capital Management’s Charles River Laboratories CRL Stock Holding History

Sandler Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-57,718
Closed -$10.7M – 130
2024
Q4 		$10.7M Buy
57,718
+52,928
+1,105% +$10.2M 1.11% 17
2024
Q3 		$943K Sell
4,790
-18,131
-79% -$3.77M 0.12% 122
2024
Q2 		$4.74M Sell
22,921
-35,410
-61% -$8.02M 0.51% 77
2024
Q1 		$15.8M Buy
58,331
+26,831
+85% +$6.41M 1.15% 23
2023
Q4 		$7.45M Buy
31,500
+12,894
+69% +$2.54M 0.62% 61
2023
Q3 		$3.65M Sell
18,606
-52,051
-74% -$10.7M 0.38% 88
2023
Q2 		$14.9M Buy
70,657
+43,420
+159% +$8.64M 1.22% 26
2023
Q1 		$5.5M Sell
27,237
-94,163
-78% -$21.3M 0.5% 65
2022
Q4 		$26.5M Buy
+121,400
New +$26.5M 2.71% 5
2022
Q3 		– Sell
-23,575
Closed -$5.04M – 91
2022
Q2 		$5.04M Sell
23,575
-58,835
-71% -$14.4M 0.54% 62
2022
Q1 		$23.4M Buy
82,410
+58,227
+241% +$18M 2.06% 11
2021
Q4 		$9.11M Sell
24,183
-95,504
-80% -$37.1M 0.79% 50
2021
Q3 		$49.4M Sell
119,687
-57,680
-33% -$24M 4.38% 1
2021
Q2 		$65.6M Sell
177,367
-20,954
-11% -$7M 5.12% 1
2021
Q1 		$57.5M Buy
198,321
+10,280
+5% +$2.86M 4.9% 1
2020
Q4 		$47M Buy
188,041
+13,700
+8% +$3.26M 5.49% 1
2020
Q3 		$39.5M Sell
174,341
-49,941
-22% -$10.4M 3.97% 3
2020
Q2 		$39.1M Buy
224,282
+42,982
+24% +$6.86M 3.72% 3
2020
Q1 		$22.9M Buy
+181,300
New +$27.2M 3.16% 7
2015
Q4 		– Sell
-17,200
Closed -$1.09M – 147
2015
Q3 		$1.09M Buy
+17,200
New +$1.24M 0.13% 113
2015
Q2 		– Sell
-50,000
Closed -$3.7M – 181
2015
Q1 		$3.96M Buy
+50,000
New +$3.69M 0.24% 150

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sandler Capital Management's CRL Position: Q1 2025 in Review

Sandler Capital Management sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 57,718 shares — an estimated $10.7M sold.

Sandler Capital Management first reported a position in CRL in Q1 2015 and held it in 21 quarters. The position peaked at $65.6M in Q2 2021. 560 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Sandler Capital Management reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • Sandler Capital Management sold 57,718 Charles River Laboratories shares in Q1 2025, an estimated $10.7M.
  • Sandler Capital Management first reported a position in Charles River Laboratories in Q1 2015 and held it in 21 quarters.
  • Sandler Capital Management's Charles River Laboratories position peaked at $65.6M in Q2 2021.
  • 560 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Sandler Capital Management's 13F filing for Q1 2025, filed 15 May 2025.